Cyteir Therapeutics Analysis
Cyteir Therapeutics is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Cyteir Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what Cyteir Therapeutics is worth, separate from its market price. There are two main types of Cyteir Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Cyteir Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Cyteir Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Cyteir Stock trading window is adjusted to America/New York timezone.
Cyteir |
Cyteir Stock Analysis Notes
About 77.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.87. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cyteir Therapeutics recorded a loss per share of 0.93. The entity last dividend was issued on the November 6, 2015. The firm had 2:1 split on the 18th of September 2014. Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. The company was incorporated in 2012 and is based in Lexington, Massachusetts. Cyteir Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 40 people. For more info on Cyteir Therapeutics please contact Markus MD at 857 285 4140 or go to https://cyteir.com.Cyteir Therapeutics Investment Alerts
| Cyteir Therapeutics is not yet fully synchronised with the market data | |
| Cyteir Therapeutics has some characteristics of a very speculative penny stock | |
| Cyteir Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Reported Net Loss for the year was (33.22 M) with loss before taxes, overhead, and interest of (16.59 M). | |
| Cyteir Therapeutics has about 166.4 M in cash with (25.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.71. | |
| Over 77.0% of the company shares are held by institutions such as insurance companies |
Cyteir Therapeutics Upcoming and Recent Events
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Cyteir Market Capitalization
The company currently falls under 'Small-Cap' category with a total capitalization of 108.71 M.Cyteir Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cyteir Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cyteir Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cyteir Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cyteir Therapeutics Outstanding Bonds
Cyteir Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cyteir Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cyteir bonds can be classified according to their maturity, which is the date when Cyteir Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Cyteir Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Odds Of Bankruptcy Now
Odds Of BankruptcyGet analysis of equity chance of financial distress in the next 2 years |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |